Navigation Links
A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year

EXTON, Pa., Sept. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds in their PatientTrends®: Hepatitis C Virus (US) 2013 report that approximately 40 percent of surveyed treatment-naive hepatitis C virus (HCV) patients and half of the prior treatment failure patients plan to receive an HCV antiviral regimen within the next year. However, the majority of these respondents did not know which regimen they will be initiating and only 9 and 14 percent, respectively, indicated they are planning to receive a treatment other than a currently-available regimen. Further, almost 40 percent of surveyed HCV patients also reported that their physician has previously recommended delaying treatment until new regimens become available and findings suggest that many patients are willing wait for safer and more effective regimens, especially if their liver disease is not advanced. The study also finds that awareness of therapies in development among HCV patients is low. Despite over two-thirds of the respondents indicating discussing products in development with their physician, more than three-quarters of the patients lacked unaided awareness of any emerging HCV products.

(Logo: )

"While most treatment-naive and prior treatment failure HCV patients who do not plan to be treated in the next year cite the future availability of better therapies as a reason, many of these patients specifically indicated waiting for interferon-free regimens to become available," said Infectious Diseases Therapy Leader Mladen Tomich, Ph.D. "However, patients overall prioritized effects on liver damage progression and reversal, and achieving sustained virologic response as the most important attributes in an HCV regimen, while exclusion of interferon or ribavirin was perceived as least important. Our research reveals that most HCV patients are prepared to endure a certain level of temporary disability as long as the treatment is efficacious."

Of note, surveyed treatment-naive HCV patients overall believe they have more influence on the management and treatment of their infection than their treating physicians. Also, the level of perceived personal influence over treatment decisions is significantly higher among surveyed treatment-naive patients than among treatment-experienced patients.

PatientTrends®: Hepatitis C Virus (US) 2013 is an annual report that includes data from 245 chronically-infected HCV patients and provides insight into patient demographics, patient-physician relationship, treatment history and plans to initiate treatment. The report also investigates the importance of drug attributes to patients, satisfaction with currently-available HCV therapies and awareness of emerging therapies, including AbbVie's ABT-267, ABT-333 and ABT-450, Boehringer Ingelheim's deleobuvir and faldaprevir, Bristol-Myers Squibb's asunaprevir and daclatasvir, Janssen/Medivir's simeprevir and Gilead's sofosbuvir and ledipasvir.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
3. "AWAKEN" Survey Finds Only 50 Percent of Americans Understand Significant Health Impact of Narcolepsy, and Many Physicians Not Comfortable Diagnosing the Sleep Disorder
4. Kewaunee Scientific Reports Significantly Improved Results for Fourth Quarter
5. South Carolinas Stop-Sale System Achieves Significant Results In Battle Against Meth
6. Tennessee Stop-Sale System Achieves Significant Results In Battle Against Meth
7. Indianas Stop-Sale System Achieves Significant Results In Battle Against Meth
8. Alabamas Stop-Sale System Achieves Significant Results In Battle Against Meth
9. Missouri Stop-Sale System Achieves Significant Results In Battle Against Meth
10. Kansas Stop-Sale System Achieves Significant Results In Battle Against Meth
11. Illinois Stop-Sale System Achieves Significant Results In Battle Against Meth
Post Your Comments:
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
Breaking Medicine News(10 mins):